Principal Investigator:
Michael Violante
Award Amount:
$100,000.00
Our company will formulate a protease inhibitor, KNI-272, to improve bioavailability following oraladministration. This will be accomplished using patented technology to convert this nearly water-insspherical, amorphous, uniformly-sized submicron particles suspended in a biocompatible aqueous…
More